

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
<i>(use as many sheets as necessary)</i>				Filing Date	June 15, 2001
				First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
Sheet	1	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code (if known)			
		4,916,122		Chu	04-10-1990	
		4,957,924		Beauchamp	09-18-1990	
		5,149,794		Yatvin et al	09-22-1992	
		5,190,926		Chu	03-02-1993	2
		5,194,654		Hostetler et al.	03-16-1993	2
		5,223,263		Hostetler et al.	06-29-1993	2
		5,256,641		Yatvin et al	10-01-2693	2
		5,411,947		Hostetler et al.	05-02-1995	2
		5,463,092		Hostetler et al.	10-31-1995	2
		5,539,116		Liotta	07-23-1996	2
		5,543,389		Yatvin et al	08-06-1996	10
		5,543,390		Yatvin et al	08-06-1996	10
		5,543,391		Yatvin et al	08-06-1996	10
		5,554,728		Basava et al.	09-10-1996	
		5,559,101		Weis et al.	09-24-1996	
		5,565,438		Chu	10-15-1996	
		5,567,688		Chu	10-22-1996	
		5,587,362		Chu	12-24-1996	
		5,939,402		Weis et al.	08-17-1999	
		6,025,335		Weis et al.	02-15-2000	
		6,194,391		Schinazi et al.	02-27-2001	
		6,245,749		Schinazi et al.	06-12-2001	
		6,297,222	B1	von Borstel et al.	10-02-2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
<i>(use as many sheets as necessary)</i>				Filing Date	June 15, 2001
Sheet	2	of	9	First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
		WO	89/02733	University of California	04-06-1989	
		WO	89/03838	A1	Pro-neuron, Inc.	05-05-1989
		WO	90/00555	Vical, Inc.	01-25-1990	
		WO	91/16920	Vical, Inc.	11-14-1991	
		WO	91/18914	Vical, Inc.	12-12-1991	
		WO	91/19721	Glazier	12-26-1991	
		WO	92/01138	Yatvin	01-20-1994	
		WO	92/08727			
		WO	92/15308	Wellcome	09-17-1992	
		WO	92/18517	Yale et al.	10-29-1992	
		WO	93/00910	Vical, Inc.	01-21-1993	
		WO	94/20523	Burroughs Wellcome	09-15-1994	
		WO	94/26273	Hostetler	11-24-1994	
		WO	94/29331	Sloan-Kettering Inst. for Cancer Research	12-22-1994	
		WO	95/07086			
		WO	96/11204	Matthes & Von Jenta-Lipinski	04-18-1996	
		WO	96/13512	Genencor	05-09-1996	
		WO	96/15132	University of California	05-23-1996	
		WO	96/40164	Emory University	12-19-1996	
		WO	98/15563	Pankiewicz, K.W. et al	10-09-1997	
		EP	0 355 131	B1	Pro-neuron, Inc.	09-04-1996
		EP	0 352 248	Medivir Aktiebolag	01-24-1990	
		EP	0 350 287	Vical, Inc.	02-10-1990	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
(use as many sheets as necessary)				Filing Date	June 15, 2001
				First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
Sheet	3	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

FOREIGN PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number				
		EP	0 494 119	BioChem Pharma	07-08-1992		
		JP	06-293645	Saneyoshi <i>et al.</i>	10-21-1994		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		ARNER and ERIKSSON, "Mammalian Deoxyribonucleoside Kinases," <i>Pharm. Ther.</i> , 1995, 67(2), 155-186.					
		BERK <i>et al.</i> , "A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria," <i>J Biol Chem.</i> , 1973, 248, 2722-2729.					
		BESTWICK <i>et al.</i> , "Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells," <i>J Biol Chem.</i> , 1982, 257, 9300-9304.					
		BLOCH, <i>et al.</i> "The Role Of The 5'-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase." <i>J. Med. Chem.</i> 10(5), 908-12 (September 1967).					
		BRIDGES <i>et al.</i> , "Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria," <i>J. Biol. Chem.</i> , February 19, 1999, 274(8), 4620-4625.					
		BRIDGES <i>et al.</i> , "Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs," <i>Proc. Am. Assoc. Cancer Res.</i> , March 1997, 38, 414.					
		BRIDGES <i>et al.</i> , "Inhibition of Mammalian DNA Polymerase-Associated 3' to 5' Exonuclease Activity by 5'-Monophosphates of 3'-Azido-3'-Deoxythymine and 3'-Amino-3'-Deoxythymidine," <i>Biochemical Pharmacology</i> , 1993, 45(8), 1571-1576.					
		BRYANT <i>et al.</i> , "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," <i>Antimicrobial Agents and Chemotherapy</i> , 45(1), 229-235 (January 2001).					
		CHANG <i>et al.</i> , "Biochemical Pharmacology of (+)- and (-)-2',3'-Dideoxy-3'-thiacytidine as Anti-hepatitis B Virus Agents," <i>J Biol Chem.</i> , November 5, 1992, 267(31), 22414-22420.					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
<i>(use as many sheets as necessary)</i>				Filing Date	June 15, 2001
Sheet	4	of	9	First Named Inventor	Jean-Pierre Sommadossi et al.
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		CHANG, et al., "Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2',3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," <i>Journal of Biological Chemistry</i> , Volume 267(20), 13938-13942 (July 15, 1992).			
		CHARIOT et al., "Zidovudine-induced mitochondrial disorder with massive liver steatosis myopathy, lactic acidosis, and mitochondrial DNA depletion," <i>J. Hepatology</i> , 1999, 30, 156-160.			
		CHEN et al., "Characterization of Pyrimidine Deoxyribonucleoside Kinase (Thymidine Kinase) and Thymidylate Kinase as a Multifunctional Enzyme in Cells Transformed by Herpes Simplex Virus Type 1 and in Cells Infected with Mutant Strains of Herpes Simplex Virus," <i>J Virol</i> , June 1979, 30, 942-945.			
		CHEN et al., "Delayed Cytotoxicity and Selective Loss of Mitochondrial DNA in Cells Treated with the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytidine," <i>J Biol Chem</i> , 1989, 264, 11934-11937.			
		CHEN et al., "The Role of Cytoplasmic Deoxycytidine Kinase in the Mitochondrial Effects of the Anti-human Immunodeficiency Virus Compound 2',3'-Dideoxycytidine," <i>J Biol Chem</i> , February 15, 1992, 267(5), 2856-2859.			
		CUI et al., "Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells," <i>J. of Pharmacology and Experimental Therapeutics</i> , 1997, 280(3), 1228-1234.			
		DAVIS et al., "In Situ Localization of Mitochondrial DNA Replication in Intact Mammalian Cells," <i>J Cell Biol</i> , 1996, 135, 883-893.			
		DAVISON, et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," <i>J. Org. Chem.</i> , 52(9), 1794-1801 (1987)			
		DOONG et al., "Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," <i>Proc. Natl. Acad. Sci.</i> , October 1991, 88, 8495-8499.			
		DU et al, Synthesis, "Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides," <i>J. of Med. Chem.</i> , (40)19, 2991-2993 (September 12, 1997).			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
(use as many sheets as necessary)				Filing Date	June 15, 2001
Sheet	5	of	9	First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		DUTSCHMAN et al., "Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L-(-)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Humna Immunodeficiency Virus β-D-(+) Nucleoside Analogs In Vitro," <i>Antimicrobial Agents and Chemotherapy</i> , July 1998, 42(7), 1799-1804.	
		FURMAN, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" <i>Antimicrobial Agents and Chemotherapy</i> , 36(12) 2686-2692 (December 1992).	
		GLONEK, et al. "Full anhydridization of methylenediphosphonic acid and of phosphoric acids by a carbodiimide" <i>Inorg.Chem.</i> , 1975 Vol. 14 (7); 1597-602.	
		GOSSELIN, G. et al. "Synthesis and Antiviral Evaluation of β-L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases", <i>Journal of Heterocyclic Chemistry</i> , 1993, 30 (Oct.-Nov.), 1229-1233.	
		HERNANDEZ-SANTIAGO et al., "Pharmacology of β-L-Thymidine and β-L-2'-Deoxycytidine in HepG2 Cell and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus," <i>Antimicrobial Agents and Chemotherapy</i> , June 2002, 46(6), 1728-1733.	
		HOARD, et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," <i>J. Am. Chem. Soc.</i> , 87(8), 1785-1788 (1965).	
		HOLY. "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," <i>Collect. Czech. Chem. Commun.</i> (1972), 37(12), 4072-87.	
		HOSTETLER, K.Y., et al. "Greatly Enhanced Inhibition Of Human Immunodeficiency Virus Type 1 Replication In CEM And HT4-6C Cells By 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, A Lipid Prodrug Of 3'-Deoxythymidine." (September 1992) <i>Antimicrob Agents Chemother</i> . 36:2025-2029.	
		HOSTETLER, K.Y., et al. "Synthesis And Antiretroviral Activity Of Phospholipid Analogs Of Azidothymidine And Other Antiviral Nucleosides." (April 15, 1990) <i>J. Biol Chem.</i> 265(11):6112-7.	
		IMAI et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." <i>J. Org. Chem.</i> , 34(6), 1547-1550 (June 1969).	
		JONES, R. et al., "Mini Review: Nucleotide prodrugs," <i>Antiviral Research</i> , 27, 1-17 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
(use as many sheets as necessary)				Filing Date	June 15, 2001
Sheet	6	of	9	First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		JUROVČIK and HOLY "Metabolism of pyrimidine L-nucleosides," <i>Nucleic Acids Research</i> , August 1976, 3(8), 2143-2153.			
		KORBA et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," <i>Antiviral Res.</i> , 15:217 (1991).			
		KRAYEVSKY and CHERNOV, "Can a Substrate Enantiomer Be a Substrate for the Same Enzyme?," <i>Molecular Biology</i> , 1996, 30(5), 585-591.			
		KRAYEVSKY and CHERNOV, "Should the Asymmetric of Enzymatic Active Centers Always Correlate with the Asymmetry of their Substrates?," <i>J. of Bionolecular Structure & Dynamics</i> , 1996, 14(2), 225-230.			
		KUCERA, L.S., et al.. "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation." <i>AIDS Res Hum Retroviruses</i> . 6:491-501 (May 1990).			
		LABENZ et al., "Analysis of the TK Enzyme Complex Induced by HSV Types 1 and 2 by Means of Isoelectric Focusing and Polyacrylamide Gel Electrophoresis," <i>Arch Virol</i> , 1982, 71, 235-249.			
		LIN et al., "Design and Synthesis of 2',3'-Dideoxy-2', 3'-dihydro-β-L-cytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human HBV and Potent Inhibitors of HIV <i>In Vitro</i> ," <i>J. Med. Chem.</i> , 39(9), 1757-1759 (April 26, 1996).			
		LIN et al., "Synthesis and Biological Evaluation of 2',3'-Dideoxy-L-pyrimidine Nucleosides as Potential Antiviral Agents against HIV and HBV," <i>J. Med. Chem.</i> , 1994, 37, 798-803.			
		LIN et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," <i>Tetrahedron Letters</i> , Vol. 51(4), 1055,1068 (1995).			
		MAGA et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," <i>Biochem. J.</i> , 294(2), 381-385 (September 1, 1993).			
		MANSOUR et al., "Stereochemical Aspects of the Anti-HCMV Activity of Cytidine Nucleoside Analogues," <i>Antiviral Chemistry & Chemotherapy</i> , 6(3), 138-142 (1995).			
		Morris S. Zedeck et al. <i>Pseudomonas testosteroni</i> , Mol. Phys. (1967), 3(4), 386-95.			
		NAKAYAMA, C., et al., "Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1-β-Xylofuranosyl-5-Alkyluracils and Related Nucleosides." <i>Nucleosides, Nucleotides</i> , 1, 139-146 (1982)			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
(use as many sheets as necessary)				Filing Date	June 15, 2001
Sheet	7	of	9	First Named Inventor	Jean-Pierre Sommadossi et al.
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		NORBECK, <i>Tetrahedron Letters</i> , 30 (46), 6246 (1989)			
		PANKIEWICZ, et al. "Efficient synthesis of methylenebis(phosphonate) analogues of P1,P2-disubstituted phyrophosphates of biological interest. (1997-04-15), 119, 3691-3692.			
		PANKIEWICZ, et al. "Synthesis of methylenebis(phosphonate) analogs of ADP Ribose" Collect. Czech. Chem. Commun. (1996-09- 23), 61; S92-S-95.			
		PAN-ZHOU et al., "Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells," <i>Antimicrobial Agents and Chemotherapy</i> , March 2000, 44(3), 496-503.			
		PLACIDI et al., "Cellular pharmacology of β-L-thymidine and β-L-2'-deoxycytidine in HepG2 cells and primary rat, monkey and human hepatocytes," 3 rd Int. Conf. Ther. Vir. Hepatitis, abstr. A122, 1999 [Antivir. Ther. 4, Suppl. 4].			
		ROBINS, "Selective Deoxygenation and Modification at C2' of Nucleosides," <i>Nucleic Acids Research Symposium Series</i> , Vol. 11, Pages 1-4, Kyoto, Japan, November 24-26, 1982, A.E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982;			
		ROBINS, M. J. et al. "Purine nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their alpha anomers." <i>J. Org. Chem.</i> March 1970, 35, 636-639.			
		ROBINS, M.J., et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides." <i>J. Am. Chem. Soc.</i> 105, 4059-4065 (1983).			
		SANEYOSHI, M., et al., "Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines." <i>Chem. Pharm. Bull.</i> , 27, 2518-2521 (1979).			
		SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine," <i>Antimicrobial Agents and Chemotherapy</i> , 36(11), 2423-2431 (1992).			
		SCHINAZI, et al., "Effect of Combinations of Acylovir with Vidarabine or its 'Monophosphate on Herpes Simplex Viruses in Cell Culture and in Mice," <i>Antimicrobial Agents and Chemotherapy</i> , 22(3), 499, (1982).			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
(use as many sheets as necessary)				Filing Date	June 15, 2001
Sheet	8	of	9	First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
				Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
		SHUTO, S., et al. "A facile one-step synthesis of 5'-phosphatidyl nucleosides by an enzymatic two-phase reaction." <i>Tetrahedron Letters</i> . 28. 199-202 (1987).			
		SODERLUND and ARNER, "Mitochondrial versus Cytosolic Activities of Deoxyribonucleoside Salvage Enzymes," <i>Purine and Pyrimidine Metabolism in Man VIII</i> , A. Shota & M. Taylor (ed.), Plenum Press, New York, 1995, 201-204.			
		SPADARI et al., "L-Thymidine is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth," <i>J. Med. Chem.</i> (1992), 35(22), 4214-4220.			
		TYRSTED et al. "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxy-adenosine and structurally related nucleoside analogs." <i>Biochim. Biophys. Acta</i> . (February 26, 1968), 155(2), 619-22.			
		VERRI et al. "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents." <i>Molecular Pharmacology</i> . (January 1997), 51(1), 132-138.			
		VERRI et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," <i>Biochem. J.</i> (1997), 328(1), 317-320 (November 15, 1997).			
		von JANTA-LIPINSKI et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified β-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α, β, γ, δ, and ε Nor HIV-1 Reverse Transcriptase," <i>J. Medicinal Chemistry</i> , 41(12), 2040-2046 (June 4, 1996).			
		Wang, S., Montelaro, R., Schinazi, R.R., Jagerski, B. and Mellors, J.W.: Activity of nucleoside and non-nucleoside reverse transcriptase inhibitors (NNRTI) against equine infectious anemia virus (EIAV). First National Conference on Human Retroviruses and Related Infections, Washington, DC, Dec. 12-16, 1993			
		ZEDECK et al. "Pseudomonas testosteroni," <i>Mol. Phys.</i> (1967), 3(4), 386-95.			
		ZHANG, W., et al. "Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol." <i>Tetrahedron Letter.</i> , 33, 1177-1180 (1992).			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/883,033
<i>(use as many sheets as necessary)</i>				Filing Date	June 15, 2001
				First Named Inventor	Jean-Pierre Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Howard V. Owens, Jr.
Sheet	9	of	9	Attorney Docket Number	06171.105026 (IDX 1005 US)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
		ZHU et al., "Anti-Hepatitis B Virus Activity and Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L-(-)-5-Fluorocytidine," <u>Antimicrobial Agents and Chemotherapy</u> , July 1998 , 42(7), 1805-1810.			
		ZHU et al., "Incorporation of Nucleoside Analogs into Nuclear or Mitochondrial DNA Is Determined by the Intracellular Phosphorylation Site," <u>J Biol Chem</u> , 2000 , 275(35), 26727-26731.			
		ZHU et al., "Inhibition of Replication of Hepatitis B Virus by Cytallene In Vitro," <u>Antimicrobial Agents and Chemotherapy</u> , August 1997 , 41(8), 1755-1760.			

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.